Search for:
Search for:
Healthcare Professionals
Publications
News
Español
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Emergency Assistance G...
Help with rent, utilities, or medication may be provided through the Emergency Assistance Program.
/Get-Help/MSF-Programs-Grants/Emergency-Assistance-Program
Shop
Privacy
Terms of Use
Site Map
Researchers find molecular key that may delay MS progression
July 25, 2018
Current treatment of multiple sclerosis is based on modulating the activity of the immune system, or preventing its cells from accessing the central nervous system and damaging it. These therapies are effective in the early phases of the disease, but they do not prevent its advance and the progressive functional deterioration. However, a new discovery could change that by reducing damage caused by MS.
During the progressive phase of the disease it is the microglial cells in the brain that are the main cause of the chronic inflammation responsible for the neurological deterioration. These microglial cells are the brain's sentries and react when faced with any damage or infection in the brain. This reaction, which is in principle beneficial, becomes harmful when it is prolonged over time, leading to chronic inflammation, and aggravates the disease and encourages its progression.
A study by an international research group coordinated from the Basque Autonomous Community identified a receptor known as P2X4 present in the microglial cells that increases their anti-inflammatory potential in order to reduce the damage in MS and encourage the body's own repair responses.
The blocking of P2X4R signals worsened clinical signs in mouse model MS, favored microglia activation of inflammation, and inhibited myelin debris elimination. Moreover, P2X4R blocking in microglia halted oligodendrocyte differentiation in vitro and remyelination after lysolecithin‐induced demyelination. Conversely, activation of P2X4R signals by ivermectin (IVM) favored a switch in microglia to an anti‐inflammatory response, activated myelin debris elimination, promoted the remyelination response, and reduced clinical signs of mouse model MS. The results provided evidence that P2X4Rs modulate inflammatory responses, and identify IVM as a potential candidate among currently used drugs to promote the repair of myelin damage.
Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the researchers said it was possible that the drugs that activate this receptor may improve the symptoms during the chronic phase of the disease when furthering the repair of the nervous tissue.
The findings were published in the journal
EMBO Molecular Medicine
.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more